Cargando…

Anesthesia in a Child with Newly Diagnosed Hypertrophic Cardiomyopathy for Placement of Implantable Cardioverter Defibrillator

Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disease usually characterized by asymmetric ventricular septal hypertrophy. HCM is an important cause of sudden cardiac death in adolescents and young adults. We are presenting a case report, ten years boy came in emergency with sudden loss o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Rajnish, Kumari, Bibha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872879/ https://www.ncbi.nlm.nih.gov/pubmed/29628595 http://dx.doi.org/10.4103/aer.AER_208_17

Ejemplares similares

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Atrial fibrillation deteriorates tricuspid regurgitation following implantable cardioverter defibrillator lead placement in patient with hypertrophic obstructive cardiomyopathy
por: Mohri, Takato, et al.
Publicado: (2017)

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
por: Weinstock, Jonathan, et al.
Publicado: (2016)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

Minimally invasive, pericardial implantable cardioverter-defibrillator placement in a young child
por: Maki, Wakana, et al.
Publicado: (2017)

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
por: Goldstein, Sarah A., et al.
Publicado: (2023)

Azygos Vein Lead Implantation For High Defibrillation Thresholds In Implantable Cardioverter Defibrillator Placement
por: Kommuri, Naga VA, et al.
Publicado: (2010)

Intrapericardial Implantation of an Implantable Cardioverter-Defibrillator in a Child
por: Seong, Yong Won, et al.
Publicado: (2011)

Obstetric hemorrhage in a case of hypertrophic obstructive cardiomyopathy with automatic implantable cardioverter defibrillator: Anaesthesia and intensive care management
por: Mishra, Sandeep Kumar, et al.
Publicado: (2016)

Tumescent local anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: An alternative for general anesthesia
por: Romero, Jorge, et al.
Publicado: (2021)

Implantation of the subcutaneous implantable cardioverter-defibrillator with retroperitoneal generator placement in a child with hypoplastic left heart syndrome
por: Reeves, Justin G., et al.
Publicado: (2015)

Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator
por: Park, Yae Min
Publicado: (2023)

Implantation of cardiac defibrillator in an infant with hypertrophic cardiomyopathy and newly identified MYBP3 mutation
por: Güvenç, Osman, et al.
Publicado: (2020)

Progressive electrical remodeling in apical hypertrophic cardiomyopathy leading to implantable cardioverter-defibrillator sensing failure during ventricular fibrillation
por: Fleeman, Blake E., et al.
Publicado: (2016)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Methemoglobinemia due to local anesthesia: a rare cause of cyanosis and chest pain after placement of implantable cardioverter defibrillator
por: Cicek, Yuksel, et al.
Publicado: (2020)

Living with hypertrophic cardiomyopathy and an implantable defibrillator
por: Magnusson, Peter, et al.
Publicado: (2017)

Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention
por: Yazaki, Kyoichiro, et al.
Publicado: (2021)

A Rare, Late Complication after Automated Implantable Cardioverter-Defibrillator Placement
por: Shapiro, Michael, et al.
Publicado: (2004)

Substernal subcutaneous implantable cardioverter-defibrillator lead placement for the management of inappropriate shocks
por: Do, Khuyen, et al.
Publicado: (2019)

A Pregnancy with Severe Hypertrophic Obstructive Cardiomyopathy after Surgery for an Implantable Cardioverter Defibrillator: A Case Report and Literature Review
por: Mitsui, Takashi, et al.
Publicado: (2016)

Inappropriate shock from delayed T-wave oversensing by a subcutaneous implantable cardioverter-defibrillator after septal myectomy for hypertrophic cardiomyopathy
por: Salgado, Benjamin C., et al.
Publicado: (2018)

Genetic Clues on Implantable Cardioverter-Defibrillator Placement in Young-Age Hypertrophic Cardiomyopathy: A Case Report of Novel MYH7 Mutation and Literature Review
por: Li, Xing, et al.
Publicado: (2021)

Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging – a case report
por: Kurath-Koller, Stefan, et al.
Publicado: (2020)

High-Risk Apical Hypertrophic Cardiomyopathy Requiring an Implantable Cardioverter-Defibrillator: A Case Report of an Overlooked Etiology
por: Rathore, Azeem, et al.
Publicado: (2023)

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
por: Higgins, Angela Y., et al.
Publicado: (2020)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Implantable cardioverter-defibrillator implantation should be considered in high-risk patients with apical hypertrophic cardiomyopathy as the same manner with the septal type
por: Park, Y M, et al.
Publicado: (2023)

Predictors of Implantable Cardioverter-Defibrillator Use in Patients with Ischemic Cardiomyopathy
por: Kelly, Ryan, et al.
Publicado: (2010)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up
por: Siontis, Konstantinos C., et al.
Publicado: (2021)

Abdominal implantable cardioverter-defibrillator placement in a patient requiring bilateral chest radiation therapy
por: Karnik, Ankur A., et al.
Publicado: (2016)

A sustained ventricular tachycardia overlooked by subcutaneous implantable cardioverter-defibrillator but recognized by co-implanted transvenous implantable cardioverter defibrillator
por: Goto, Kentaro, et al.
Publicado: (2020)

Implantable cardioverter-defibrillator prevents sudden death in patients with Chagas cardiomyopathy in the Brazilian Amazon
por: Couceiro, Katia do Nascimento, et al.
Publicado: (2021)

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
por: Gandhi, Kaushang, et al.
Publicado: (2010)

Transvenous implantable cardioverter-defibrillator implantation in a patient with arrhythmogenic cardiomyopathy and massive right atrial thrombus
por: Hayashi, Hiroshi, et al.
Publicado: (2020)

Novel Implantable Cardioverter-defibrillator Lead Placement in a Patient with a Prosthetic Tricuspid Valve
por: Patel, Pratik, et al.
Publicado: (2017)

Approaches to Minimizing Periprocedural Complications During Subcutaneous Implantable Cardioverter-defibrillator Placement
por: Vedachalam, Srikanth, et al.
Publicado: (2020)

Perioperative and postoperative pain in patients undergoing subcutaneous implantable cardioverter-defibrillator placement
por: Bisignani, A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qpdaeeufijs1i6em9cqa6mr39